NasdaqFinancialsLife & Health InsuranceS&P SmallCap 600
$36.75
+2.03 (+5.85%)
Close of Nov 06, 2026 · end-of-day data
TRUP 8-K filings, explained
Every material Form 8-K Trupanion has filed with the SEC since April 04, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Trupanion reported third-quarter 2026 results for the period ended September 30, 2026. Total revenue rose 11% to $405.6 million, net income was $9.3 million, or $0.21 per diluted share, compared with $5.9 million, or $0.13 per diluted share, a year earlier. The company also repurchased about $25.0 million of its stock in the quarter, leaving about $75.0 million available under its $100.0 million buyback program.
Total revenue was $405.6 million, up 11% from $366.9 million in Q3 2025.
Net income was $9.3 million, or $0.21 per diluted share, versus $5.9 million, or $0.13 per diluted share, in Q3 2025.
Adjusted EBITDA was $20.8 million, compared with $19.6 million in Q3 2025.
Operating cash flow was $30.7 million and free cash flow was $28.5 million in Q3 2026; about $25.0 million of stock was repurchased in the quarter.
Trupanion reported second-quarter 2026 results with total revenue of $392.9 million, up 11% from a year earlier, but net income fell to $6.8 million, or $0.16 per diluted share, from $9.4 million, or $0.22, in the second quarter of 2025. The Board also approved a share repurchase program of up to $100.0 million with no expiration date, which gives the company authority to buy back stock but does not commit it to a specific amount.
Total revenue was $392.9 million, up 11% from the second quarter of 2025; subscription business revenue was $276.7 million, up 14%.
Net income was $6.8 million, or $0.16 per diluted share, versus $9.4 million, or $0.22, in the second quarter of 2025.
The Board approved a repurchase program of up to $100.0 million of common stock in June 2026, with no expiration date.
The New York Department of Financial Services approved a $44 million extraordinary dividend from American Pet Insurance Company to Trupanion in July 2026.
Trupanion reported first quarter 2026 results on April 30, 2026. Total revenue rose 12% to $384.0 million and the company swung to net income of $4.9 million, or $0.11 per diluted share, from a net loss of $1.5 million a year earlier, while adjusted EBITDA rose to $17.4 million from $12.2 million. Total enrolled pets fell 2% year over year, though subscription pets rose 5%.
Total revenue $384.0 million, up 12% from the first quarter of 2025
Net income $4.9 million, or $0.11 per diluted share, versus a net loss of $1.5 million, or $(0.03) per share, a year earlier
Adjusted EBITDA $17.4 million, versus $12.2 million in the first quarter of 2025
Operating cash flow $14.6 million and free cash flow $13.7 million, versus $16.0 million and $14.0 million a year earlier; total enrolled pets were 1,637,665, down 2%
Director Max Brodén told Trupanion on April 22, 2026 that he will not stand for re-election at the June 10, 2026 annual meeting, citing personal reasons. He will remain on the board until that meeting, and the filing says Aflac's strategic partnership with Trupanion is unaffected. The same day, Trupanion filed its 2025 Annual Report, which includes a shareholder letter, but the 8-K does not report any financial results.
Director Max Brodén will not stand for re-election; notice given April 22, 2026
Brodén's departure is for personal reasons, not a disagreement with Trupanion or the board
Annual Stockholders' Meeting set for 9 am Pacific Time on June 10, 2026
2025 Annual Report with shareholder letter filed April 27, 2026
Trupanion reported fourth-quarter and full-year 2025 results on February 12, 2026. Fourth-quarter total revenue rose 12% to $376.9 million, and net income was $5.6 million, or $0.13 per diluted share, compared with $1.7 million, or $0.04, a year earlier. Full-year 2025 net income was $19.4 million, or $0.45 per share, versus a net loss of $9.6 million in 2024, though that result includes a $7.8 million realized gain from exchanging a preferred stock investment for intellectual property.
Q4 2025 adjusted EBITDA was $21.8 million, compared with $19.4 million in Q4 2024.
Full-year 2025 total revenue was $1,439.3 million, up 12%; subscription revenue was $989.3 million, up 16%.
Total enrolled pets fell 2% to 1,647,565 at December 31, 2025, while subscription enrolled pets rose 5% to 1,096,173.
Q4 2025 operating cash flow was $29.3 million and free cash flow was $25.3 million; the company held $370.7 million in cash and short-term investments at year-end.
Trupanion reported third-quarter 2025 revenue of $366.9 million, up 12% from a year earlier, and net income of $5.9 million, or $0.13 per diluted share, versus $1.4 million, or $0.03, in the same quarter of 2024. On November 4, 2025, the company entered a credit agreement with PNC Bank providing a $100.0 million term loan and a $20.0 million revolving facility, maturing November 4, 2028, and used it to repay its 2022 credit agreement; the new loans are secured by substantially all company assets and carry covenants.
Q3 2025 total revenue $366.9 million, up 12%; net income $5.9 million, diluted EPS $0.13 (Q3 2024: $1.4 million, $0.03)
Nine-month net income $13.8 million, or $0.32 per diluted share, versus a net loss of $11.3 million in the prior-year period
On November 4, 2025, borrowed $100.0 million under the term facility and $15.0 million under the revolver; loans bear interest at SOFR plus 2.75% per annum
Quarterly term loan principal payments of $2.5 million; 2022 credit agreement with Piper Sandler Finance, LLC repaid in full and terminated
Trupanion's board appointed Bradley S. Powell as a director on October 29, 2025. Powell previously served as CFO of Expeditors International of Washington from October 2008 to September 2025, and the company describes him as bringing accounting and financial expertise to the board. The filing says he is an independent director and will serve until the 2026 annual meeting of stockholders.
Appointed to the board on October 29, 2025; term expires at the 2026 annual meeting of stockholders
Served as CFO of Expeditors International of Washington from October 2008 to September 2025
Previously CFO of Eden Bioscience Corporation from July 1998 to September 2008
Filing states he is an independent director under Nasdaq rules and will join the non-employee director compensation program
Trupanion reported second-quarter 2025 results, with total revenue up 12% year over year and net income of $9.4 million, compared with a net loss a year earlier. Net income includes a $7.8 million realized gain from exchanging a preferred stock investment for intellectual property, so the profit figure is partly non-operating. Total enrolled pets fell 2% from a year earlier, while subscription enrolled pets rose 4%.
Total revenue was $353.6 million for the quarter ended June 30, 2025, up 12% from $314.8 million a year earlier.
Net income was $9.4 million, or $0.22 per diluted share, versus a net loss of $5.9 million, or $(0.14) per share, in Q2 2024.
Adjusted EBITDA was $16.6 million, compared with $7.4 million in Q2 2024.
Cash and short-term investments totaled $319.6 million at June 30, 2025, with an additional $15 million available under its credit facility.
Trupanion reported first quarter 2025 results for the period ended March 31, 2025. Total revenue rose 12% to $342.0 million, and the net loss narrowed to $1.5 million, or $0.03 per share, from $6.9 million, or $0.16 per share, a year earlier. The filing does not include updated financial guidance.
Total revenue was $342.0 million, up 12% from the first quarter of 2024; subscription business revenue was $233.1 million, up 16%.
Net loss was $1.5 million, or $0.03 per share, versus $6.9 million, or $0.16 per share, in the first quarter of 2024.
Adjusted EBITDA was $12.2 million, compared with $4.8 million a year earlier; free cash flow was $14.0 million.
Total enrolled pets were 1,667,637 at March 31, 2025, down 2% year over year, while subscription enrolled pets rose 5% to 1,052,845.
Trupanion reported fourth quarter 2024 revenue of $337.3 million, up 14% from a year earlier, and net income of $1.7 million, or $0.04 per diluted share, compared with a net loss of $2.2 million in the same quarter of 2023. For full year 2024, net loss narrowed to $9.6 million from $44.7 million, and revenue rose 16% to $1.29 billion, which points to improved profitability for shareholders.
Q4 2024 adjusted EBITDA was $19.4 million, compared with $8.5 million in Q4 2023.
Full year 2024 net loss was $9.6 million, or $0.23 per share, versus $44.7 million, or $1.08 per share, in 2023.
Full year 2024 free cash flow was $38.6 million, compared with $0.4 million in 2023.
Q4 2024 included a $5.3 million goodwill impairment charge.
Trupanion reported third-quarter 2024 results for the period ended September 30, 2024, with total revenue up 15% from a year earlier and a net profit after a net loss in the same quarter of 2023. Subscription revenue grew 20%, and the company reported $13.4 million in free cash flow for the quarter. The filing furnishes the results press release as Exhibit 99.1 and does not include updated guidance.
Total revenue was $327.5 million, up 15% from the third quarter of 2023.
Net income was $1.4 million, or $0.03 per diluted share, compared with a net loss of $4.0 million, or $0.10 per share, a year earlier.
Adjusted EBITDA was $14.5 million, compared with $6.1 million in the third quarter of 2023.
Free cash flow was $13.4 million in the quarter, compared with $7.0 million a year earlier.
Trupanion appointed John Gallagher as Chief Operating Officer effective September 4, 2024. He will lead the North American growth teams and oversee the Contact Center and Claims support teams, and has been with the company since 2016.
Gallagher's base salary rises from $300,000 to $375,000, and his bonus target rises from 50% to 75% of base salary.
He will receive RSUs with an approximate value of $575,000, expected to be granted in early November 2024.
RSUs vest over four years, with 25% vesting on the one-year anniversary of grant and the rest vesting quarterly thereafter.
Trupanion reported second quarter 2024 results for the period ended June 30, 2024. Total revenue rose 16% from a year earlier to $314.8 million, and the net loss narrowed to $5.9 million, or $0.14 per share, from $13.7 million, or $0.33 per share, in the second quarter of 2023. Shareholders get improved revenue, profit and cash flow measures, though the filing gives no forward guidance.
Total revenue was $314.8 million, up 16% from $270.6 million in the second quarter of 2023.
Net loss was $5.9 million ($0.14 per share), compared with $13.7 million ($0.33 per share) a year earlier.
Adjusted EBITDA was $7.4 million, compared with a loss of $3.2 million in the second quarter of 2023.
Free cash flow was $4.0 million, compared with negative $8.1 million a year earlier; subscription revenue rose 20% to $208.6 million.
Trupanion said Darryl Rawlings' resignation as chief executive became effective August 1, 2024, and Margi Tooth, the company's president, became CEO, as part of a previously disclosed succession plan. The board also appointed Ms. Tooth as a director, and her compensation was set in connection with the role change.
Margi Tooth became CEO effective August 1, 2024; she was appointed a director on July 30, 2024, effective the same date.
Her base salary rises from $400,000 to $550,000, effective August 1, 2024.
She receives RSUs valued at $1,500,000 (divided by share price per the filing's formula), vesting over four years with 25% after one year.
Ms. Tooth is not independent under NASDAQ rules and will not serve on Board committees.
Trupanion reported first quarter 2024 total revenue of $306.1 million, up 19% from a year earlier, and a net loss of $6.9 million, narrowed from $24.8 million. The board also appointed President Margi Tooth as chief executive effective August 1, 2024, succeeding founder Darryl Rawlings, who will remain Chair of the Board.
Q1 2024 total revenue was $306.1 million, up 19% from $256.3 million in Q1 2023.
Net loss was $6.9 million, or $(0.16) per share, versus a net loss of $24.8 million, or $(0.60) per share, a year earlier.
Adjusted EBITDA was $4.8 million, compared with $(4.9) million in Q1 2023.
Darryl Rawlings resigned as CEO effective August 1, 2024 and will receive a $200,000 annual consulting fee for pet food program work.
Two Trupanion board members, Dan Levitan and Dr. Zay Satchu, told the company on April 2, 2024 that they will not stand for re-election at the 2024 Annual Stockholders' Meeting in June 2024. The filing says the decision was not the result of any disagreement with Trupanion or the board, and both intend to keep serving as directors until that meeting.
Directors Dan Levitan and Dr. Zay Satchu will not seek re-election.
Notice was given on April 2, 2024; the 2024 Annual Meeting is set for June 2024.
The filing states no disagreement with the company or the board led to the decisions.
Both directors plan to remain on the board until the annual meeting.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Trupanion filing is on SEC EDGAR ↗. 8-K briefs of other companies →